8-K: Iridex Announces Preliminary Q1 2025 Results, Expects Revenue Between $11.8M and $12.0M

Iridex Corporation announces preliminary unaudited operational and financial results for Q1 2025, projecting revenue between $11.8 million and $12.0 million.

Summary

• Iridex Corporation announced preliminary, unaudited operational and financial results for the first fiscal quarter ended March 29, 2025.
• Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024.
• The company sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarter.
• Approximately 24 Cyclo G6 Laser Systems were sold, compared to 22 in the prior year quarter.
• Cash and cash equivalents as of March 29, 2025, were $7.2 million.
• The company will hold an investor call on April 16, 2025, to introduce Iridex and Novel's strategic vision.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the stabilization of the business, improved financial condition, and revenue increases. However, the company acknowledges external risks and the preliminary nature of the results.

Positives

• The business is stabilizing.
• The company's financial condition has improved following the strategic investment by Novel Inspiration International Co., Ltd.
• Top-line revenue has increased versus the prior year in each of the last two quarters.
• Operating expenses have been significantly reduced.
• The company is capable of achieving breakeven or better performance at historical revenue levels.

Risks

• The company is exposed to external factors like changes in tariff policies.
• Preliminary results are subject to further internal review, potential adjustments, and review by the company's external auditors.
• Actual results may differ materially from those described in forward-looking statements due to a number of factors.

Future Outlook

The company aims to achieve breakeven or better performance at historical revenue levels, even while significantly reducing operating expenses.

Management Comments

• President and CEO Patrick Mercer stated that the pre-announcement was to highlight the stabilization of the business and the company's improved financial condition following the strategic investment by Novel Inspiration International Co., Ltd.
• Patrick Mercer noted that the company has delivered top line revenue increases versus the prior year in each of the last two quarters, even while significantly reducing operating expenses.
• Patrick Mercer mentioned that the company remains capable of achieving breakeven or better performance at historical revenue levels.

Industry Context

Iridex operates in the ophthalmology market, providing laser-based medical systems for the treatment of glaucoma and retinal diseases. The announcement highlights the company's efforts to stabilize its business and improve its financial condition, which is crucial in a competitive market.

Comparison to Industry Standards

• It's difficult to provide a detailed comparison without knowing the specific growth rates and profitability metrics of Iridex's direct competitors like Lumenis, Ellex (now part of Nova Eye Medical), and Topcon in the glaucoma and retinal disease treatment market.
• However, the announcement suggests that Iridex is focused on improving its financial performance and achieving breakeven, which is a common goal for companies in the medical device industry.

Stakeholder Impact

• Shareholders will be interested in the company's stabilization and improved financial condition.
• Employees may be reassured by the company's efforts to achieve breakeven performance.
• Customers can expect continued availability of Iridex's products and services.

Next Steps

• The company will hold an investor call on April 16, 2025, to discuss Iridex and Novel's strategic vision.
• The preliminary results are subject to further internal review and review by the company's external auditors.

Key Dates

Keywords

Iridex, financial results, Cyclo G6, revenue, laser systems, medical devices, ophthalmology